Get the Stockscreener App
45.78
1.20%
-0.70
Maze Therapeutics Inc stock is traded at $45.78, with a volume of 26,782.
It is down -1.20% in the last 24 hours and up +4.48% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$46.48
Open:
$46.21
24h Volume:
26,782
Relative Volume:
0.06
Market Cap:
$2.21B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.18%
1M Performance:
+4.48%
6M Performance:
+189.17%
1Y Performance:
+286.86%
1-Day Range:
$45.33
$46.34
1-Week Range:
$43.00
$46.65
52-Week Range:
$6.71
$49.25
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
45.90 | 2.24B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.18 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.05 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
731.90 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.49 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.53 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-25 | Initiated | Wells Fargo | Overweight |
| Nov-14-25 | Initiated | Raymond James | Outperform |
| Sep-02-25 | Initiated | BTIG Research | Buy |
| Jul-23-25 | Initiated | H.C. Wainwright | Buy |
| Jul-08-25 | Initiated | Wedbush | Outperform |
Maze Therapeutics Inc Stock (MAZE) Latest News
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside - TipRanks
MAZE: Lead kidney and metabolic disease programs advance toward pivotal data with strong financial backing - TradingView
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up Following Analyst Upgrade - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Given New $58.00 Price Target at Guggenheim - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Sees Significant Growth in Short Interest - MarketBeat
Aug Update: What analysts say about Maze Therapeutics Inc stockWeekly Profit Recap & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Pullback Watch: Is Iveda Solutions Inc a good ESG investmentMarket Weekly Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Maze Therapeutics, Inc. (MAZE) Stock Analysis: Biotech Innovator with a 10.77% Potential Upside - DirectorsTalk Interviews
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Maze Therapeutics Inc CEO set for TD Cowen Health Care event - Traders Union
MAZE Technical Analysis & ETF Price Forecast - Intellectia AI
Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst - TipRanks
Maze Therapeutics, Inc. (MAZE) Stock Analysis: A Biotech With A 9.78% Upside Potential - DirectorsTalk Interviews
Is Maze Therapeutics Inc. forming bullish engulfing patterns2025 Year in Review & Stepwise Entry and Exit Trade Signals - mfd.ru
Latest MAZE ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
Zifo Partners With Maze Therapeutics on Managing Biobank Data - Contract Pharma
Zifo and Maze Therapeutics Partner to Power Precision Medicine - The Malaysian Reserve
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge - AOL.com
Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Earnings Recap: How liquid is Maze Therapeutics Inc stockQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge - The Motley Fool
Maze Therapeutics Stock Just Shot Up 24% Pre-Market Today – Here’s What Happened - MSN
MAZE Should I Buy - Intellectia AI
Maze Therapeutics (MAZE) Valuation Check After Strong 1 Year Shareholder Return - Yahoo Finance
Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit - MarketBeat
Frazier Life Sciences discloses Maze Therapeutics (MAZE) 9% ownership and warrants cap - Stock Titan
Bull Bear: What analysts say about Maze Therapeutics Inc stockGlobal Markets & Weekly High Return Opportunities - baoquankhu1.vn
Assessing Maze Therapeutics (MAZE) Valuation After Strong Recent Share Price Momentum - Sahm
IPO Launch: Is Maze Therapeutics Inc forming a bullish divergenceJuly 2025 WrapUp & Consistent Return Investment Signals - baoquankhu1.vn
Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Maze Therapeutics, Inc. (MAZE): Investor Outlook on Strong Buy Ratings and 12.50% Upside Potential - DirectorsTalk Interviews
Maze Therapeutics Secures New $200 Million Loan Facility - The Globe and Mail
Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 15,000 Shares of Stock - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Maze Therapeutics Signs Loan and Security Agreement With Hercules Capital - TradingView
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Maze Therapeutics stock hits all-time high at 47.47 USD By Investing.com - Investing.com Nigeria
Maze Therapeutics stock hits all-time high at 47.47 USD - Investing.com
Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month HighShould You Buy? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Stock - Defense World
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock - AOL.com
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $332,025.00 in Stock - MarketBeat
Strs Ohio Decreases Stake in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics, Inc. (MAZE): Investor Outlook And 9.88% Potential Upside - DirectorsTalk Interviews
Washington University Takes Position in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics stock price target reiterated at $60 by H.C. Wainwright - Investing.com Canada
Equities Analysts Set Expectations for MAZE FY2030 Earnings - MarketBeat
Maze Therapeutics Rings the Closing Bell - Nasdaq
Maze Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Raised to "Hold" at Wall Street Zen - MarketBeat
Maze Therapeutics Inc Stock (MAZE) Financials Data
There is no financial data for Maze Therapeutics Inc (MAZE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Maze Therapeutics Inc Stock (MAZE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bernstein Harold | President, R&D & CMO |
Feb 02 '26 |
Sale |
46.02 |
15,000 |
690,334 |
0 |
| Bachrodt Amy | SVP, Finance |
Feb 02 '26 |
Option Exercise |
10.42 |
5,000 |
52,100 |
17,965 |
| Bachrodt Amy | SVP, Finance |
Feb 02 '26 |
Sale |
46.04 |
5,000 |
230,219 |
12,965 |
| Dandekar Atul | CSBO |
Jan 29 '26 |
Option Exercise |
10.42 |
7,500 |
78,150 |
18,003 |
| Dandekar Atul | CSBO |
Jan 29 '26 |
Sale |
44.27 |
7,500 |
331,990 |
10,503 |
| Bachrodt Amy | SVP, Finance |
Jan 22 '26 |
Option Exercise |
10.42 |
5,000 |
52,100 |
17,965 |
| Bachrodt Amy | SVP, Finance |
Jan 22 '26 |
Sale |
45.52 |
5,000 |
227,612 |
12,965 |
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):